Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Changes in Stockholders' Equity

v3.20.2
Condensed Consolidated Statement of Changes in Stockholders' Equity - USD ($)
$ in Thousands
Series A Preferred Stock [Member]
Common Stock [Member]
Shares Issuable [Member]
Treasury Stock [Member]
Paid-In Capital [Member]
Accumulated Deficit [Member]
Non-Controlling Interests [Member]
Total
Balance at Dec. 31, 2018 $ 1 $ 58 $ 659   $ 397,408 $ (396,274) $ 17,891 $ 19,743
Balance (in shares) at Dec. 31, 2018 1,000,000 57,845,447            
Stock-based compensation expense         10,423     10,423
Issuance of restricted stock   $ 2     (2)      
Issuance of restricted stock (in shares)   1,842,034            
Issuance of common stock under ESPP         60     60
Issuance of common stock under ESPP (in shares)   54,221            
Issuance of subsidiaries' common shares for license expenses     (164)   164      
Issuance of common stock for at-the-market offering, net   $ 9     15,789     15,798
Issuance of common stock for at-the-market offering, net (in shares)   8,604,469            
Preferred A dividends declared and paid         (1,773)     (1,773)
Partner company's sale of stock, net         61,036     61,036
Partner company's at-the-market offering, net         29,680     29,680
Issuance of partner company warrants in conjunction with Horizon Notes         888     888
Common shares issuable for 2017 Subordinated Note Financing interest expense     500         500
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (495)   1,468     974
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   1,330,450            
Common shares issuable for 2019 Notes interest expense     281         281
Common shares issued for 2019 Notes interest expense     (281)   506     225
Common shares issued for 2019 Notes interest expense (in shares)   262,088            
Common shares issued for Opus debt         500     500
Common shares issued for Opus debt (in shares)   396,825            
Non-controlling interest in subsidiaries         (70,702)   70,702  
Deconsolidation of Caelum non-controlling interest             4,849 4,849
Net loss attributable to non-controlling interest             (44,237) (44,237)
Net loss attributable to common stockholders           (24,468)   (24,468)
Issuance of preferred A for at-the-market offering, net         523     523
Issuance of preferred A for at-the-market offering, net (in shares) 26,111              
Write off of Partner company note receivable         (2)     (2)
Balance at Sep. 30, 2019 $ 1 $ 70 500   445,966 (420,742) 49,205 75,000
Balance (in shares) at Sep. 30, 2019 1,026,111 70,335,534            
Balance at Jun. 30, 2019 $ 1 $ 68 490   439,295 (407,980) 57,946 89,820
Balance (in shares) at Jun. 30, 2019 1,000,000 68,138,203            
Stock-based compensation expense         3,741     3,741
Issuance of restricted stock (in shares)   177,292            
Issuance of common stock for at-the-market offering, net   $ 1     1,930     1,931
Issuance of common stock for at-the-market offering, net (in shares)   1,213,643            
Preferred A dividends declared and paid         (601)     (601)
Partner company's offering, net         52     52
Partner company's at-the-market offering, net         3,341     3,341
Common shares issuable for 2017 Subordinated Note Financing interest expense     500         500
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (490)   489      
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   317,804            
Common shares issued for Opus interest expense (in shares)   91,767            
Common shares issuable for Opus interest expense         165     165
Common shares issued for Opus debt         500     500
Common shares issued for Opus debt (in shares)   396,825            
Non-controlling interest in subsidiaries         (3,467)   3,467  
Net loss attributable to non-controlling interest             (12,208) (12,208)
Net loss attributable to common stockholders           (12,762)   (12,762)
Issuance of preferred A for at-the-market offering, net         523     523
Issuance of preferred A for at-the-market offering, net (in shares) 26,111              
Write off of Partner company note receivable         (2)     (2)
Balance at Sep. 30, 2019 $ 1 $ 70 500   445,966 (420,742) 49,205 75,000
Balance (in shares) at Sep. 30, 2019 1,026,111 70,335,534            
Balance at Dec. 31, 2019 $ 1 $ 74 500   461,874 (436,234) 46,317 72,532
Balance (in shares) at Dec. 31, 2019 1,341,167 74,027,425            
Stock-based compensation expense         10,319     10,319
Issuance of common stock related to equity plans   $ 2     (2)      
Issuance of common stock related to equity plans (in shares)   2,307,231            
Issuance of common stock under ESPP         90     90
Issuance of common stock under ESPP (in shares)   53,268            
Issuance of common stock for at-the-market offering, net   $ 17     43,183     43,200
Issuance of common stock for at-the-market offering, net (in shares)   16,378,234            
Preferred A dividends declared and paid         (4,507)     (4,507)
Repurchase of Series A preferred stock, net       $ (70) (2)     (72)
Repurchase of Series A preferred stock (in shares) (5,000)              
Retirement of Series A preferred stock       $ 70        
Retirement of Series A preferred stock         (70)      
Issuance of Series A preferred stock for cash, net $ 2       35,466     35,468
Issuance of Series A preferred stock for cash, net (in shares) 2,090,971              
Partner company's offering, net         53,698     53,698
Partner company's at-the-market offering, net         33,500     33,500
Partner company's preferred stock offering, net         7,088     7,088
Partner company's dividends declared and paid         50     50
Reclass partner company's warrants from liability to equity         1,216     1,216
Issuance of partner company's common shares for research and development expenses         42     42
Partner company's exercise of warrants for cash         13     13
Partner company's ESPP         349     349
Issuance of partner company warrants in conjunction with Horizon Notes               0
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (500)   1,816     1,317
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   982,216            
Common shares issuable for service     18         18
Issuance of warrants in conjunction with Oaktree Note         4,419     4,419
Non-controlling interest in subsidiaries         (73,981)   73,981  
Net loss attributable to non-controlling interest             (41,264) (41,264)
Net loss attributable to common stockholders           (41,231)   (41,231)
Balance at Sep. 30, 2020 $ 3 $ 94 18   574,461 (477,465) 79,034 176,145
Balance (in shares) at Sep. 30, 2020 3,427,138 93,748,374            
Balance at Jun. 30, 2020 $ 3 $ 86 813   521,493 (461,918) 56,381 116,858
Balance (in shares) at Jun. 30, 2020 2,693,806 86,113,331            
Stock-based compensation expense         3,171     3,171
Issuance of common stock related to equity plans (in shares)   268,800            
Issuance of common stock under ESPP         180     180
Issuance of common stock for at-the-market offering, net   $ 7     21,110     21,117
Issuance of common stock for at-the-market offering, net (in shares)   7,064,214            
Preferred A dividends declared and paid         (1,719)     (1,719)
Issuance of Series A preferred stock for cash, net         11,965     11,965
Issuance of Series A preferred stock for cash, net (in shares) 733,332              
Partner company's offering, net         18,774     18,774
Partner company's at-the-market offering, net         23,053     23,053
Partner company's preferred stock offering, net         7,088     7,088
Partner company's dividends declared and paid         50     50
Reclass partner company's warrants from liability to equity         1,216     1,216
Issuance of partner company's common shares for research and development expenses         21     21
Common shares issued for 2017 Subordinated Note Financing interest expense   $ 1 (500)   810     311
Common shares issued for 2017 Subordinated Note Financing interest expense (in shares)   302,029            
Write off common shares issuable for 2019 Notes interest expense     (313)         (313)
Common shares issuable for service     18         18
Issuance of warrants in conjunction with Oaktree Note         4,419     4,419
Non-controlling interest in subsidiaries         (37,070)   37,070  
Net loss attributable to non-controlling interest             (14,417) (14,417)
Net loss attributable to common stockholders           (15,547)   (15,547)
Balance at Sep. 30, 2020 $ 3 $ 94 $ 18   $ 574,461 $ (477,465) $ 79,034 $ 176,145
Balance (in shares) at Sep. 30, 2020 3,427,138 93,748,374